As an emerging therapeutic target for metabolic diseases and age-related metabolic decline, ERRα holds promise for treating conditions such as obesity, muscle wasting, and CVDs, by improving mitochondrial function and oxidative metabolism. This evidence concerns the gene ESRRA and Other metabolic disease.